Development of a 111In-labeled peptide derivative targeting a chemokine receptor, CXCR4, for imaging tumors
- 31 May 2006
- journal article
- Published by Elsevier in Nuclear Medicine and Biology
- Vol. 33 (4) , 489-494
- https://doi.org/10.1016/j.nucmedbio.2006.01.006
Abstract
No abstract availableKeywords
This publication has 34 references indexed in Scilit:
- Messenger RNA Expression Levels of CXCR4 Correlate with Metastatic Behavior and Outcome in Patients with OsteosarcomaClinical Cancer Research, 2005
- Effect of Chemokine Receptors CXCR4 and CCR7 on the Metastatic Behavior of Human Colorectal CancerClinical Cancer Research, 2005
- Expression of CXCR4 Predicts Poor Prognosis in Patients with Malignant MelanomaClinical Cancer Research, 2005
- A single treatment with microcapsules containing a CXCR4 antagonist suppresses pulmonary metastasis of murine melanomaBiochemical and Biophysical Research Communications, 2004
- Corrigendum to “conformational study of a highly specific CXCR4 inhibitor, T140, disclosing the close proximity of its intrinsic pharmacophores associated with strong anti-HIV activity”: [Bioorg. Med. Chem. Lett. 11 (2001) 359]Bioorganic & Medicinal Chemistry Letters, 2001
- Chemokine receptorsCytokine & Growth Factor Reviews, 2001
- ChemokinesImmunity, 2000
- Two murine homologues of the human chemokine receptor CXCR4 mediating stromal cell-derived factor 1α activation of Gi2 are differentially expressedin vivoEuropean Journal of Immunology, 1997
- HIV-1 Entry Cofactor: Functional cDNA Cloning of a Seven-Transmembrane, G Protein-Coupled ReceptorScience, 1996
- [111In]-DTPA-labeled analogues of α-melanocyte-stimulating hormone for melanoma targeting: Receptor bindingin vitro andin vivoInternational Journal of Cancer, 1994